Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472198 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT01472198 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 250 participants.
The verdict
NCT01472198, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer. The treatment phase of this study will be comprised of 2 sequential parts: an open label treatment phase and a double-blinded treatment phase.
Interventions
- DRUG Gemcitabine
- DRUG Simtuzumab
- DRUG Placebo to match simtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01472198
The ClinicalTrials.gov registry entry for NCT01472198 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT01472198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01472198 about?
NCT01472198 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma". This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer. The treatment phase of this study will be comprised of 2 sequential parts: an open label treatment phase and a double-blinded treatment phase.
What is the current status of trial NCT01472198?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2011-11. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01472198?
The interventions under investigation include: Gemcitabine (DRUG), Simtuzumab (DRUG), Placebo to match simtuzumab (DRUG).
Who is sponsoring clinical trial NCT01472198?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.